Background: In preparation for therapeutic use of tigecycline (first in class glycylcycline) in Japan, a retrospective sample of clinical isolates (2003)(2004) was tested by the SENTRY Antimicrobial Surveillance Program. All tests were by reference methods.
Conclusions:
Using US-FDA breakpoints, tigecycline-resistant rates among Japanese isolates were nil for Enterobacteriaceae and only 0.3% for GPC. Tigecycline appears to be active against current pathogens from Japan including prevalent resistance phenotypes (extended-spectrum ß-lactamases, MRSA, penicillin-resistant pneumococci).
InTRoDuCTIon
Tigecycline is a semisynthetic glycylcycline derived from minocycline that induces its bacteriostatic effect by binding to a high affinity intracellular site on the bacterial 30S-ribosome, thus blocking entry of amino-acyl tRNA molecules into the A site of the ribosome and preventing further protein synthesis. Tigecycline overcomes the two major determinants of tetracycline resistance: active efflux and protection of ribosomes.
Tigecycline is an important advance in treatment for a range of infections where mixed and/or resistant organisms play a role, and include a very broad spectrum comprising virtually all Gram-positive bacteria, most Gram-negative bacteria including anaerobes, and many strains harbouring resistance to other antimicrobial classes. In preparation for expanded clinical trials in Japan and the Asia-Pacific (APAC) region, the SENTRY Antimicrobial Surveillance Program retrospectively tested year 2003 and 2004 strains from Japan against tigecycline.
MATERIALS AnD METhoDS
Bacterial isolates. A total of 1,033 bacterial isolates collected during [2003] [2004] in three medical centers located in Japan (Nagasaki University, Nagasaki; Kitasato University, Kanagawa; and Teikyo University, Tokyo) were evaluated as part of the SENTRY Antimicrobial Surveillance Program. The isolates were consecutively collected from bloodstream infections, skin and soft tissue infections, urinary tract infections and pneumonia in hospitalized patients according to a common protocol. Only isolates from documented infections were included in the study. Species identification was confirmed by standard biochemical tests and the Vitek System (bioMerieux, Hazelwood, MO), when necessary.
Antimicrobial susceptibility testing. All isolates were susceptibility tested using the broth microdilution method as described by the Clinical and Laboratory Standards Institute (CLSI). Fresh cation-adjusted MuellerHinton broth was used in validated panels manufactured by TREK Diagnostics (Cleveland, OH). Categorical interpretations for comparator antimicrobials were those found in M100-S18; breakpoints for tigecycline were those of the United States (US) Food and Drug Administration (FDA). Quality control (QC) was performed using Escherichia coli ATCC 25922, S. aureus ATCC 29213 and Pseudomonas aeruginosa ATCC 27853; all QC results were within specified ranges as published in M100-S18. All strains were tested either at the Women's and Children's Hospital (Adelaide, Australia) or at JMI Laboratories (North Liberty, Iowa, USA).
Data were analyzed for MIC 50 , MIC 90 and percentage susceptible and resistant according to US-FDA tigecycline product labeling interpretive criteria (2005). Enterobacteriaceae with elevated MIC values (≥2 mg/L) for ceftazidime and/or ceftriaxone and/or aztreonam were considered as extended-spectrum ß-lactamase (ESBL)-producing phenotypes (see Table 2 ).
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SELECTED REFEREnCES
Clinical and Laboratory Standards Institute. (2006 the US-FDA product package insert, "tigecycline has decreased in vitro activity against Morganella spp., Proteus spp. and Providencia spp." (Table 1 ).
• H. influenzae were inhibited by tigecycline at ≤2 mg/L, including 33 isolates that were ampicillin-resistant (only four produced ß-lactamase). BLNAR and BLN-amoxicillin/clavulanate-resistant strains are very common (45.2%) in Japan.
• Acinetobacter spp. had a bimodal MIC distribution for tigecycline e.g. 0.06-0.25 and 1-4 mg/L without resistance (0.0%) by US-FDA/ Jones et al. definitions for Enterobacteriaceae. • Tigecycline was also active against most Enterobacteriaceae at ≤2 mg/L and all strains had MIC values at ≤4 mg/L (Table 1) .
• Tigecycline appears to be a promising glycylcycline for use in Japan, including application against isolates having resistances to other antimicrobial classes.
